Sign Out
1) Concomitant use of sumatriptan and MAO-A inhibitors may decrease sumatriptan clearance and increase half-life and blood concentrations of the drug.
2) Ergot alkaloids (e.g. ergotamine, dihydroergotamine, methylsergide) have been reported to cause prolonged vasospastic reactions and the vasoconstrictor effects of these drugs may be additive to those of sumatriptan, therefore use of ergot alkaloids and sumatriptan within 24 hours of each other is contraindicated.
3) Serotonin syndrome has been reported during concurrent therapy with 5-HT1 receptor agonists and selective serotonin-reuptake inhibitors (SSRIs) or selective serotonin- and norepinephrine-reuptake inhibitors (SNRIs).
Continue with Google